Completed PHASE2 INTERVENTIONAL 3-arm NCT00560638

Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye

A Double-Masked, Randomized, Placebo-Controlled Study of Loteprednol Etabonate Ophthalmic Suspension, 0.5% for the Treatment of Dry Eye Used Either TID or QID for a 2 Week Period

Sponsor: Bausch & Lomb Incorporated

Conditions Dry Eye

Interventions loteprednol etabonate ophthalmic suspension, 0.5% vehicle of loteprednol etabonate

Updated 6 times since 2017 Last updated: Jul 14, 2011 Started: Nov 30, 2005 Primary completion: Feb 28, 2006 Completion: Feb 28, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Dry Eye, this trial is completed. The trial is conducted by Bausch & Lomb Incorporated and has accumulated 6 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bausch & Lomb Incorporated

Data source: Bausch & Lomb Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Andover, United States